(Q74534637)
Statements
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment (English)
V Kunzmann
T Ruediger
M Hallek
H K Mueller-Hermelink
1 September 2001